{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:14:47Z","timestamp":1792800887201,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011542","name":"Center for Clinical and Translational Science, Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.xkme.2026.101481","type":"journal-article","created":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T13:39:57Z","timestamp":1785073197000},"page":"101481","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Rituximab as Rescue Therapy for Atezolizumab-Induced IgA Vasculitis"],"prefix":"10.1016","volume":"8","author":[{"given":"Cristina R.","family":"Ortiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6921-7230","authenticated-orcid":false,"given":"Jose","family":"Arriola-Montenegro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3700-4537","authenticated-orcid":false,"given":"Sandra M.","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.xkme.2026.101481_bib1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.kint.2024.09.017","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated nephrotoxicity: a position statement from the American Society of Onco-nephrology","volume":"107","author":"Herrmann","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.xkme.2026.101481_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fneph.2022.1017921","article-title":"Immune checkpoint inhibitor related nephrotoxicity: advances in clinicopathologic features, noninvasive approaches, and therapeutic strategy and rechallenge","volume":"2","author":"Miao","year":"2022","journal-title":"Front Nephrol"},{"issue":"2","key":"10.1016\/j.xkme.2026.101481_bib3","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study","volume":"31","author":"Cortazar","year":"2020","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.xkme.2026.101481_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003467","article-title":"Acute kidney injury in patients treated with immune checkpoint inhibitors","volume":"9","author":"Gupta","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.xkme.2026.101481_bib5","doi-asserted-by":"crossref","first-page":"16","DOI":"10.34067\/KID.0000152019","article-title":"Acute interstitial nephritis and checkpoint inhibitor therapy: single center experience of management and drug rechallenge","volume":"1","author":"Manohar","year":"2020","journal-title":"Kidney360"},{"issue":"1","key":"10.1016\/j.xkme.2026.101481_bib6","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/ndt\/gfy105","article-title":"Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis","volume":"34","author":"Manohar","year":"2019","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.xkme.2026.101481_bib7","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ekir.2020.10.002","article-title":"A systematic review of immune checkpoint inhibitor-associated glomerular disease","volume":"6","author":"Kitchlu","year":"2020","journal-title":"Kidney Int Rep"},{"issue":"2","key":"10.1016\/j.xkme.2026.101481_bib8","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000543323","article-title":"Immune checkpoint inhibitor-related acute kidney injury: management and challenges","volume":"57","author":"Youssef","year":"2026","journal-title":"Am J Nephrol"},{"issue":"1","key":"10.1016\/j.xkme.2026.101481_bib9","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40425-018-0478-8","article-title":"Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience","volume":"7","author":"Mamlouk","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.xkme.2026.101481_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2024.152440","article-title":"A scoping review of vasculitis as an immune-related adverse event from checkpoint inhibitor therapy of cancer: unraveling the complexities at the intersection of immunology and vascular pathology","volume":"66","author":"Lee","year":"2024","journal-title":"Semin Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.xkme.2026.101481_bib11","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1093\/ndt\/gfae184","article-title":"Immune checkpoint inhibitor-associated nephritis-treatment standard","volume":"39","author":"Barbir","year":"2024","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.xkme.2026.101481_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000750","article-title":"Checkpoint inhibitor-related renal vasculitis and use of rituximab","volume":"8","author":"Mamlouk","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.xkme.2026.101481_bib13","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/art.40766","article-title":"Dampening of CD8+ T cell response by B cell depletion therapy in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"71","author":"N\u00e9el","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.xkme.2026.101481_bib14","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1136\/annrheumdis-2016-209925","article-title":"Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis","volume":"76","author":"van Daalen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.xkme.2026.101481_bib15","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","article-title":"Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade","volume":"26","author":"House","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.xkme.2026.101481_bib16","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.kint.2025.05.029","article-title":"Urinary C-X-C-motif ligand 9 (CXCL9) in immune checkpoint inhibitor-associated acute interstitial nephritis","volume":"108","author":"Gupta","year":"2025","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.xkme.2026.101481_bib17","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.ekir.2022.11.020","article-title":"Cytokines and immune cell phenotype in acute kidney injury associated with immune checkpoint inhibitors","volume":"8","author":"Farooqui","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"4","key":"10.1016\/j.xkme.2026.101481_bib18","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.ekir.2021.01.013","article-title":"Biomarkers, clinical features, and rechallenge for immune checkpoint inhibitor renal immune-related adverse events","volume":"6","author":"Isik","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1016\/j.xkme.2026.101481_bib19","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s40425-019-0613-1","article-title":"B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors","volume":"7","author":"Damsky","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.xkme.2026.101481_bib20","doi-asserted-by":"crossref","first-page":"799","DOI":"10.34067\/KID.0003962021","article-title":"Is rechallenge appropriate in patients that develop immune checkpoint inhibitor-associated AKI?: PRO","volume":"3","author":"Herrmann","year":"2021","journal-title":"Kidney360"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059526002438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059526002438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:34:12Z","timestamp":1790876052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059526002438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2590059526002438"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2026.101481","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab as Rescue Therapy for Atezolizumab-Induced IgA Vasculitis","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2026.101481","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101481"}}